#DrugSafety #Nimesulide #ClinicalPharmacy #PharmD #Pharmacist #MedicalEducation #Healthcare #Medicine #RegulatoryUpdate #PatientSafety #EvidenceBasedMedicine #MedKutumb #MBBS #Doctors To view or add a comment, sign in 26,866 followers More from this author Global Pharmacovigilance: Key Regulatory Shifts to Watch in 2025 Vizen Life Sciences Pvt Ltd 1y The Growing Need for Comprehensive Pharmacovigilance and QPPV Services in Emerging Markets like Tanzania, Kenya, Uganda, and Egypt Vizen Life Sciences Pvt Ltd 1y "Harnessing AI for Enhanced Pharmacovigilance: FDA's Emerging Drug Safety Technology Program" Vizen Life Sciences Pvt Ltd 2y
There is no FDA approval for human treatment, and it should not be used as a cure for any disease
In a phase 3 randomized, controlled clinical trial, participants treated with tirzepatide achieved an average weight loss of around 20% of their body weight over 72 weeks
The US rate of obesity stands at more than 40% versus the UK at 26%, Germany at 23%, and France at 10%
or use of dynamic activities to improve functional performance, each for 15 minutes) for the same session or date, modifier 59 is only appropriate if the therapist performs the two procedures in distinctly different 15-minute intervals
For now, the most accurate statement is that both treatments produce approximately 20 to 23% weight loss in non-diabetic populations with obesity, and both are in a class far beyond anything that came before them